![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Merck Forges Deal to License COVID-19 Antiviral to Medicines Patent Pool
Merck Forges Deal to License COVID-19 Antiviral to Medicines Patent Pool
October 29, 2021
Merck has struck a licensing pact with the Medicines Patent Pool (MPP), a United Nations-supported public health organization serving the developing world, to expand access to its experimental COVID-19 antiviral pill, molnupiravir, co-developed with Ridgeback Biotherapeutics.
The precedent-setting agreement marks the first licensing deal for a COVID-19 treatment inked with the MPP, which has previously distributed HIV, tuberculosis and hepatitis C drugs to poorer nations.
Under the deal, 105 low- and middle-income countries will gain access to the treatment, following authorization from the World Health Organization and/or national regulators.
Upcoming Events
-
21Oct